JPMorgan Starts BioNTech (BNTX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BNTX Hot Sheet
Price: $88.12 -1.73%
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
JPMorgan analyst Cory Kasimov initiates coverage on BioNTech (NASDAQ: BNTX) with a Overweight rating and a price target of $23.00.
For an analyst ratings summary and ratings history on BioNTech click here. For more ratings news on BioNTech click here.
Shares of BioNTech closed at $16.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
- Northland Starts Unusual Machines (UMAC) at Outperform
- Raymond James Starts CAMP4 Therapeutics Corp (CAMP) at Strong Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
